How to Know If Antidepressants Are Working With PHQ-9 and GAD-7
What the two questionnaires measure, why the withClaro app uses them, and why regular scores help most when you take them to your doctor.
By Alena A. Kozlova · Medically reviewed by Dr. Jason Tan , Consultant Psychiatrist · 2026-11-20 · 13 min read
Key takeaways The PHQ-9 and GAD-7 are short, validated questionnaires for depression and anxiety symptoms, and NHS Talking Therapies uses both at every session. For one person, a change of 5 points or more on the PHQ-9 is usually taken as a real change, rather than normal ups and downs. Regular scores help most when you bring them to appointments and your clinician uses them to adjust treatment. The withClaro app reminds you to complete both questionnaires every two weeks and adds your scores and how they have changed to the pre-appointment report.
On this page
What do the PHQ-9 and GAD-7 measure? What do PHQ-9 and GAD-7 scores mean? Why does the withClaro app use these two questionnaires? How do PHQ-9 scores show your antidepressant is working? What do people find hard about regular questionnaires? How do PHQ-9 and GAD-7 work in the withClaro app? What should you bring to your appointment? What do clinicians see in the report?
One way to know if antidepressants are working is to fill in the same two short questionnaires, the PHQ-9 and the GAD-7, at regular intervals and compare the scores with your doctor. Antidepressants build their effect over weeks, and from the inside it can be hard to tell whether anything is shifting. These questionnaires turn a vague sense of being a bit better or a bit worse into numbers you and your doctor can compare over time. The withClaro app uses both because they are among the most widely used symptom questionnaires, including in the NHS.
Medical review Medical content reviewed by Dr. Jason Tan, Consultant Psychiatrist, on October 30, 2026. The Reddit count and app data analysis are by the withClaro team.
What do the PHQ-9 and GAD-7 measure?
The PHQ-9 is a nine-question self-report scale for depression. Each question covers one of the nine symptoms used to diagnose major depression and is scored from 0 to 3, so the total runs from 0 to 27. The GAD-7 works the same way for anxiety, with seven questions scored from 0 to 3 and a total from 0 to 21.
Both forms open by asking how often each problem has bothered you over the last two weeks, so a score describes a fortnight rather than a single day.
What do PHQ-9 and GAD-7 scores mean?
On the PHQ-9, a total of 0 to 4 is usually read as minimal, 5 to 9 as mild, 10 to 14 as moderate, 15 to 19 as moderately severe and 20 to 27 as severe. On the GAD-7, scores of 5, 10 and 15 can be read as mild, moderate and severe anxiety.
Severity PHQ-9 (depression) GAD-7 (anxiety) Minimal 0 to 4 0 to 4 Mild 5 to 9 5 to 9 Moderate 10 to 14 10 to 14 Moderately severe 15 to 19 not used Severe 20 to 27 15 to 21
The original 2001 PHQ-9 study included 6,000 patients in US primary care and gynaecology clinics. 580 of them were also interviewed by a mental health professional, and in that group a score of 10 or more picked up about 9 in 10 people who had major depression, and correctly ruled it out in about 9 in 10 who did not. NICE, the UK guideline body, uses a PHQ-9 score of 16 as the line between less severe and more severe depression.
A 2006 study of 2,740 adults in US primary care found that the GAD-7 identified generalised anxiety disorder with 89% sensitivity and 82% specificity. The same study found that anxiety and depression often come together but affect daily functioning separately, which is why the withClaro app asks both questionnaires and does not fold anxiety into a single mood score.
Neither questionnaire is a diagnosis. A score shows how much symptoms are bothering you over a set period, and a diagnosis comes from a clinician's assessment. Treat your score as the start of a conversation with your doctor about what it reflects.
The ninth PHQ-9 question asks about thoughts of self-harm. If you mark it in the withClaro app, the app shows an alert suggesting you contact emergency services. If you are having these thoughts now, find a crisis line in your country , or in the US call or text 988.
Why does the withClaro app use these two questionnaires?
We chose the PHQ-9 and GAD-7 because they are short, they were tested against interviews with mental health professionals, and they are already part of standard practice in the UK. A clinician who opens a report with these scores reads them on a familiar scale, without a key or an explanation from the app.
Talking Therapies is a therapy service, but the same questionnaires are also used in many GP and psychiatry services. The PHQ-9 is used for everyone and the GAD-7 is the default measure for anxiety. Measuring at every session has given these services outcome data on 98.5% of people who have a course of treatment. The manual also notes that services which measured only at the start and the end tended to overestimate how well treatment worked, because people with missing final scores had often done less well.
NICE recommends that people starting an antidepressant usually have their first review within 2 weeks, to check whether symptoms are improving and for side effects. It should be after 1 week for people aged 18 to 25, or where there is a particular concern about suicide. Clinicians are asked to consider routine outcome monitoring with a validated measure, naming the PHQ-9 as an example. The wording is consider rather than must, and GAD-7 is not named in that recommendation.
The PHQ-9 also tracks change well. A 2004 study of 434 older adults in depression treatment found that changes in PHQ-9 scores separated people whose depression persisted from those in partial or full remission, and that scores were stable when retaken a week apart. At your next appointment, ask whether your clinician uses the PHQ-9 or GAD-7 in their own notes, so your scores and theirs line up.
How do PHQ-9 scores show your antidepressant is working?
One score shows where you are over the fortnight it asks about. A series of scores taken at regular intervals shows direction: whether symptoms ease after a dose change, hold flat or creep back. For one person, a change of 5 points on the PHQ-9 is considered clinically meaningful, which gives you and your doctor a threshold to look for.
Timing matters as well. In STAR\*D, a study of 2,876 people taking citalopram in US clinics, many people responded or reached remission at 8 weeks or later. NICE says that if an antidepressant is going to work, it usually starts to help within 4 weeks, and that if it has not helped at all by then at a full dose, it is worth reviewing with your prescriber. A single score in week three cannot show that kind of slow change, and a line of scores over two or three months can.
What is measurement-based care?
Doctors call this approach measurement-based care: symptoms are measured with a standard scale at regular intervals, and the scores are used to make treatment decisions. In a 2015 trial of 120 outpatients with moderate to severe depression in Beijing, 73.8% reached remission at 24 weeks with measurement-based care and 28.8% with standard care, and the measurement group reached remission in 10.2 weeks rather than 19.2. That trial used other rating scales, not the PHQ-9, and doctors in the measurement group changed doses more often.
A 2021 review that pooled seven trials of 2,019 adults on medication found that measurement-based care was linked to more people having few or no symptoms left, milder symptoms overall, and people being more likely to keep taking their medicine. The number of people who improved by half or more did not differ. The authors noted that there were few trials, and most (5 of 7) had design weaknesses that could make the results look better than they are.
Not every study finds a difference. A 2016 Cochrane review of 17 trials found no clear difference in symptoms when people's questionnaire results were shared with their clinician. Most of those trials were in specialist mental health or talking therapy services rather than GP care, and most used general wellbeing questionnaires rather than the PHQ-9. In the PROMDEP trial across 141 GP practices in England and Wales, people who completed the PHQ-9 twice with feedback had similar depression scores at 12 weeks to those who did not. Their quality of life was better at 26 weeks, and patients said they valued comparing their first and later scores.
Fill in both questionnaires when the reminder comes, including the weeks when nothing seems to change. Some side effects can show up in your score. Sleeping more or less, feeling tired, changes in appetite, trouble concentrating and feeling restless are all PHQ-9 questions, so a score can move because of side effects as well as mood. Log side effects in the app so your doctor can tell the two apart. Do not stop your antidepressant or change the dose because of a score. Talk to your prescriber first, as stopping suddenly can cause withdrawal symptoms.
What do people find hard about regular questionnaires?
Filling in the same two questionnaires every few weeks is not always easy. We read 80 public Reddit posts in which people described their own experience of the PHQ-9 or GAD-7, from communities including r/depression, r/antidepressants, r/Anxiety, r/MentalHealthUK, r/NHS, r/TalkTherapy, r/therapy, r/Spravato and r/TMSTherapy. Frustration and doubt came up alongside encouragement. People choose what they post, so these counts reflect the conversation online rather than everyone who uses the questionnaires.
What people wrote about Posts (of 80) Seeing the numbers move 22 Not sure how to answer or what the score meant 19 Questions did not fit their situation 17 A high or stuck score was upsetting 10 Not always answering honestly 10 The repetition felt tiring 9 Filled in the forms and heard nothing back 7
The most common difficulty was knowing how to answer. In 19 of 80 posts, people were unsure what counts as a day, whether to include symptoms with another cause such as the flu, or what their score meant. In 17 of 80, people felt the questions did not fit them: physical illness, pregnancy, ADHD or panic attacks pushed their score up or down, and symptoms that had become milder but still showed up most days left the score where it was.
Others wrote about the effort and the feelings around it. In 9 of 80 posts the repetition felt tiring, and in 10 of 80 a high score, or one that stopped falling, was upsetting or frightening to see. In 10 of 80, people described not always answering honestly, for example lowering their answers out of shame or fear of being put on medication. In 7 of 80, people filled in the forms and then heard nothing about the results.
The single most common theme, in 22 of 80 posts, was seeing the numbers move. Falling scores made improvement feel concrete. For some, a score that stayed high gave them something firm to bring to their prescriber when asking whether to change medication.
The measurement-based care trials point the same way: the benefits appeared where doctors used the scores to make treatment decisions.
If a question does not fit your situation, answer for the period it asks about and add a note in your daily check-in, so you can explain the score to your doctor. If seeing your score is upsetting, or you have been softening your answers, say so at the appointment, and ask your doctor to go through your scores with you rather than leaving them in the file.
Observation: early data from the withClaro app
Between July and October 2026, 24 people in the withClaro app completed the PHQ-9 again at least 7 days after an earlier attempt. Their average score fell from 13.2 to 8.4, a drop of 4.8 points (95% confidence interval for the change: -7.3 to -2.3 points). 10 of the 24 halved their score. On average people completed the questionnaire about three times; this figure is approximate.
This is an early signal, and it does not show an effect. Its limits:
The group is small: 24 people. Only people who came back to the questionnaire are included, and people who stopped may have done differently. There is no comparison group. The observation period is short. The drop cannot be attributed to monitoring or to the app. It may reflect the treatment itself, the natural course of depression, or regression to the mean, where people who start with a high score tend to score lower next time. The number of completions differed from person to person.
The direction of change matches what studies of measurement-based care describe, and it does not confirm them.
How do PHQ-9 and GAD-7 work in the withClaro app?
Every two weeks the withClaro app sends a notification to your home screen reminding you to complete the PHQ-9 and the GAD-7, which matches the two-week period both questionnaires ask about. Between those reminders, the daily check-in records mood, energy, sleep and appetite, and you can log side effects against your dose and treatment phase.
If you start tracking when you start treatment, the two-week rhythm means you will usually have a second score in time for your first review, which NICE says is usually within 2 weeks of starting an antidepressant.
Before an appointment, the withClaro app builds a pre-appointment report, a PDF for your doctor. When you have completed the PHQ-9 and GAD-7, the report includes a separate block with your scores and how they have changed. Around it, the report shows your mood and sleep quality over the report period next to the period before, your dose log and how often doses were taken as scheduled, the side effects you logged with the day each first appeared, and the topics you want to discuss. The report also shows your doctor your answer to the ninth PHQ-9 question and anything in your notes they may want to ask you about. No one reads your answers or notes as you enter them, so if you need help, find a crisis line or in the US call or text 988 rather than waiting for your appointment.
Turn on notifications for the withClaro app so the reminder reaches you on the day it is due.
What should you bring to your appointment?
Scores help most when they are part of the appointment itself. A 2017 review of 51 studies found that symptom scores fed back to the clinician during medication management and therapy appointments improved outcomes, while one-off screening, infrequent measurement and scores sent outside the appointment did not. Bring your scores in a form your doctor can read in the first few minutes.
Less than 20% of mental health practitioners use measurement-based care routinely, so your doctor may not ask for scores. You can offer them. Before the appointment, gather:
the pre-appointment report, with your PHQ-9 and GAD-7 scores in it the topics you want to discuss, added before the report is generated so they appear in it the date of any dose change or switch, so the scores can be read against it any change of 5 points or more on the PHQ-9, in either direction what was happening in your life during the weeks your scores moved, since the numbers do not show it whether you answered anything other than 'not at all' to the ninth PHQ-9 question, even once, and how you are feeling now
Ask your doctor what change in scores they would expect by your next review, so you both know what you are looking for. For the conversation itself, see how to prepare for a medication management appointment .
What do clinicians see in the report?
A pre-appointment report from the withClaro app is a PDF summary of patient-reported information and app-logged data for a set period before the appointment. When the patient has completed the PHQ-9 and GAD-7, it includes a separate block with their scores and how they have changed, alongside the rest of the report.
The rest covers a short overview written from the patient's check-in notes, a daily dose log with adherence, a mood and sleep quality chart compared with the previous period, a side effects table, a clinical context table for other medications, allergies, diagnoses and substance use, and the topics the patient wants to discuss. Where the records do not line up, for example when check-in notes name a different medication from the one stored in the app, the report says so.
The safety screen is an AI review of the questionnaire answers, check-in notes and any clinician notes supplied. The report states that it is not a structured clinical risk assessment: a result of not detected means no concern appeared in the available material, not that safety was assessed. The report also states that it is not a medical diagnosis and does not replace clinical judgment, and treatment decisions stay with you.
The PROMDEP authors suggested that future patient-reported measures in UK primary care should include anxiety symptoms and be completed remotely. In the withClaro app the GAD-7 sits next to the PHQ-9, and both are completed at home between visits.
Ask patients who use the withClaro app to send the report before the appointment, so you can read the scores ahead of the visit.
Get the withClaro app The withClaro app reminds you to complete the PHQ-9 and GAD-7 every two weeks and adds your scores to a pre-appointment report for your doctor.
Frequently asked questions How do I know if my antidepressants are working? Look at direction over several weeks rather than at a single day. A drop of 5 points or more on the PHQ-9 counts as a meaningful change for one person, and NICE says that if an antidepressant is going to work, it usually starts to help within 4 weeks, although full improvement can take longer. If you have noticed no benefit at all after about 4 weeks at a full dose, ask your prescriber for a review. Don't stop or change your dose on your own. Bring your scores from the whole period to your next review.
Is there a quiz to check if my antidepressant is working? The PHQ-9 and GAD-7 are the closest thing, though they measure your symptoms rather than giving a verdict on the medication. Complete both at the same interval and compare the results with your doctor.
Can the PHQ-9 diagnose depression? No. It measures how much depression symptoms are bothering you, and a diagnosis comes from a clinician's assessment. Use your score as a starting point when you describe your symptoms to your doctor.
Does a high score mean my antidepressant isn't working? Not on its own. Scores can stay high in the early weeks, and life events or side effects can push them up. If your scores rise or stay high across several check-ins, book a review and bring the dates of any dose changes. In the first few weeks of starting an antidepressant or changing the dose, some people feel more anxious, agitated or restless, and a small number have new or worse thoughts of suicide, especially people under 25. If this happens, contact your prescriber straight away. If you are having thoughts of ending your life or hurting yourself, use the urgent contacts in the section above.
Can tracking my mood make me feel worse? For some people it can. A review of mood-tracking apps in young people found they may help by increasing awareness of one's own emotions, and noted that in adults tracking could increase negative feelings for some users. If filling in the questionnaires leaves you feeling worse, tell your doctor and agree together how often to complete them.
Related articles
Sources Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med, 2001 Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med, 2006 Generalized Anxiety Disorder 7-item (GAD-7) scale, official English form. PHQ Screeners National Institute for Health and Care Excellence. Depression in adults: treatment and management (NG222), 2022 NHS England, National Collaborating Centre for Mental Health. NHS Talking Therapies for anxiety and depression Manual, version 7, updated March 2024 Löwe B, Unützer J, Callahan CM, Perkins AJ, Kroenke K. Monitoring depression treatment outcomes with the Patient Health Questionnaire-9. Med Care, 2004 Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D. Am J Psychiatry, 2006 Guo T, Xiang YT, Xiao L, et al. Measurement-Based Care Versus Standard Care for Major Depression: A Randomized Controlled Trial With Blind Raters. Am J Psychiatry, 2015 Zhu M, Hong RH, Yang T, et al. The Efficacy of Measurement-Based Care for Depressive Disorders: Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Clin Psychiatry, 2021 Kendrick T, et al. Routine use of patient reported outcome measures (PROMs) for improving treatment of common mental health disorders in adults. Cochrane Database Syst Rev, 2016 Kendrick T, Dowrick C, Lewis G, Moore M, et al. Patient-reported outcome measures for monitoring primary care patients with depression: the PROMDEP cluster RCT and economic evaluation. Health Technol Assess, 2024 Fortney JC, Unützer J, Wrenn G, et al. A Tipping Point for Measurement-Based Care. Psychiatr Serv, 2017 Lewis CC, Boyd M, Puspitasari A, et al. Implementing Measurement-Based Care in Behavioral Health: A Review. JAMA Psychiatry, 2019 Dubad M, Winsper C, Meyer C, Livanou M, Marwaha S. A systematic review of the psychometric properties, usability and clinical impacts of mobile mood-monitoring applications in young people. Psychol Med, 2018
withClaro articles are for self-monitoring and educational purposes only. They are not a medical device, therapist, or diagnostic tool, and do not replace care from your prescribing clinician. If you are in crisis, contact your care team, emergency services, the Samaritans (UK: 116 123), or the Crisis Text Line (US: text HOME to 741741).